Formosa and Medvisis Partner for Clobetasol Propionate Ophthalmic Suspension to Treat Post-Operative Inflammation and Pain
Shots:
- Formosa Pharmaceuticals and Medvisis have entered into an exclusive licensing agreement for the commercialization of APP13007 (ophthalmic suspension, 0.05%) to treat post-surgical ocular inflammation and pain, in Switzerland & Liechtenstein
- The agreement includes undisclosed upfront, sales milestones, and other considerations throughout the duration
- APP13007 was approved by the US FDA in Mar & launched in Sep 2024. It consists of clobetasol propionate developed using Formosa’s APNT nanoparticle formulation platform for twice-daily dosing over 14 days, offering rapid, sustained relief from inflammation & pain
Ref: Formosa | Image: Formosa and Medvisis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
